Standard BioTools Inc. Common Stock (LAB) — 分析摘要
Standard BioTools Inc. Common Stock（LAB）的市值为326.17百万美元，最近一年的营收同比增长了-51.1%。净利润率为-87.8%。当前市盈率为4.2倍。
核心要点
- 营收同比变化-51.1%
- 净利润率-87.8%
- 市盈率4.2倍
与LABORATORY ANALYTICAL INSTRUMENTS板块的其他公司相比，LAB的营收增长为-51.1%，市盈率为4.2倍。
Standard BioTools Inc. Common Stock (LAB)
更新 — ET · 来源 POLYGON
红旗与风险提示高风险信号
存在多项实质性红旗，在依赖任何估值输出前应先重点核查这些风险。
营业利润率为 -136.7% — 严重经营亏损
营收较上一期下降 23.0%。
最新报表显示自由现金流为负。
经营现金流为负，但净利润仍为正。
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.
行业
LABORATORY ANALYTICAL INSTRUMENTS
员工人数
389
总部
BOSTON, MA
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。